PEPTIDESTAT
InvestigationalWeight lossSubcutaneousEvidence 4/5

Survodutide

Also known as: BI 456906

Co-activates GLP-1 and glucagon receptors; in Phase 2 produced substantial weight reduction and improvement in MASH endpoints.

Browse guidesBuy / compare source
Survodutide
Drug class
Dual agonist (GLP-1 / glucagon)
Primary targets
GLP-1R, GCGR
Dose reference
0.6–4.8 mg once weekly (trial)
Half-life
~7 days
Developer / origin
Boehringer Ingelheim / Zealand Pharma
Reference year
2023
Evidence score
4/5 - Human RCT evidence, investigational
Evidence 4/5

Human RCT evidence, investigational

Survodutide has randomized human weight-loss evidence and ongoing phase 3 development, but it is still investigational.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • Human randomized trial evidence
  • Phase 3 program rationale
  • No approved indication yet

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Survodutide guides

Read the matching guide or adjacent research pages for more context.

GLP-1 for Weight Loss: The 2026 Complete GuideGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. Here's how to think about them honestly — eligibility, results, cost, side effects, and what happens when you stop.What Is GLP-1? Complete Guide to the Hormone, the Drugs, and What They DoGLP-1 is a hormone your gut releases after eating. GLP-1 agonist drugs amplify its effect — slowing digestion, reducing appetite and improving blood sugar. This is the complete guide.Retatrutide: What the Research Actually ShowsRetatrutide is an investigational triple-agonist peptide drawing major attention for weight loss. Here's what the clinical research actually shows.Best GLP-1 for Weight Loss in 2026: Honest Head-to-HeadZepbound currently leads on average weight loss in trials. Wegovy has the best cardiovascular evidence. Here's the honest head-to-head of every approved GLP-1 for weight loss.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Details

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Details

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Details

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.